Navigation Links
China Pharma Holdings, Inc. Reports Full Year 2011 Financial Results

HAIKOU, China, March 15, 2012 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. (NYSE AMEX: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced financial results for the year ended December 31, 2011.

Full Year Highlights

  • Revenue increased 9% to $81.2 million in fiscal year 2011 from $74.4 million in fiscal year 2010.
  • Income from operations was $22.0 million in fiscal year 2011 compared to $24.7 million in 2010, a decrease of $2.7 million, or 11%.
  • Net income was $19.3 million in fiscal year 2011 compared to $23.4 million in 2010, a decrease of $4.1 million, or 18%. Earnings per common share was 44 cents per basic and diluted share in fiscal 2011 compared with 54 cent per share, a decrease of 18%.
  • Gross profit margin was 36% in fiscal year 2011, a decrease from 41% in fiscal 2010.
  • "In 2011 we registered a moderate top line growth in a very challenging year for the pharmaceutical industry in China. Once again our diversified product portfolio demonstrated its robustness in a difficult environment," said Ms. Zhilin Li, China Pharma's Chairman and CEO.  "The healthcare reform has produced encouraging results in improving the standards of living for people in China. The changes produced by the reform, however, have created pricing pressures on nearly all pharmaceutical products across the industry, and we expect this environment to continue for some time to come. Going forward, we expect the launches of new products such as Candesartan, our new hypertension drug, and Rosuvastatin, our generic version of Crestor, to enhance our profitability and growth opportunities. Commercializing exciting new drugs like our antibiotic combination drug, along with first-to-market generic medicines, is an important part of China Pharma's growth and profitability strategy." 

    Full Year ResultsRevenues for the year ended December 31, 2011 were $81.2 million, up 9% from revenues of $74.4 million for the year ended December 31, 2010, reflecting higher sales in three out of four product categories. 

    The "Digestive Diseases" product group remains the Company's fastest growing revenue category in 2011, with sales increasing 33% to $12.4 million from $9.3 million in 2010.  The strong performance of the Digestive Diseases product group primarily reflects incremental revenue from Tiopronin, and Compound Ammonium Glycyrrhetate, both prescribed for the treatment of Hepatitis and liver dysfunction diseases.  Sales of "Anti-Viro/Infection & Respiratory" products, the Company's largest revenue category during 2011, grew 18% to $32.0 million from $27.1 million in 2010. The "CNS Cerebral and Cadio Vascular" product group ("CNS") generated sales of $25.8 million in 2011, representing an increase of 8% compared to sales of $23.9 million in 2010. We expect the upcoming new CNS products (namely Candesartan and Rosuvastatin) will further support the profitability and sales in this category once launched. Sales from the "Other" product category was $11.0 million in 2011 compared to $14.1 million in 2010, a decrease of 22%,  as all products in this category encountered stronger competition this year compared to the last year.

    Gross profit for the year ended December 31, 2011 was $29.0 million, compared to gross profit of $30.3 million in 2010, a decrease of 4%. Gross margin was 36% in 2011, compared to 41% for 2010, a decrease of five percentage points, reflecting pricing pressure during the year.

    Selling, general and administrative expenses in 2011 were $7.2 million, or 8.8% of sales, compared to $5.6 million, or 7.5% of sales, in 2010.  For the year ended December 31, 2011, the Company's bad debt expense was $0.1 million, compared to a bad debt expense of $0.5 million in 2010.

    Operating income was $22.0 million in 2011 compared to $24.7 million in 2010, a decrease of 11%. The lower operating income in 2011 reflects lower gross margin and higher operating expenses.

    For the year ended December 31, 2011, the Company paid income tax at a rate of approximately 15%.  Income tax expense for the year ended December 31, 2011 was $3.4 million. While for the year ended December 31, 2010, our income tax was at a rate of approximately 11%, and our income tax expense was $2.7 million for the year ended December 31, 2010. The Company obtained "National High-Tech Enterprise" status from the PRC government in the fourth quarter of 2010.  With this designation, the Company is entitled to a preferential tax rate of 15% from 2011 until 2013, which is notably lower than the statutory income tax rate of 25%.

    Net income for the year 2011 was $19.3 million, or $0.44 per basic and diluted share, compared to $23.4 million, or $0.54 per basic and diluted share in 2010.

    Financial ConditionAs of December 31, 2011, the Company had cash and cash equivalents of $4.1 million compared to $3.7 million as of December 31, 2010. Year-over-year, working capital increased to $97 million in 2011 from $79 million in 2010 and the current ratio rose to 8.0 times from 7.1 times.

    Accounts receivable balance rose to $69.7 million in 2011 from $61.9 million at the end of 2010. The Company's management team continues to be focused on improving accounts receivable collection and expects to make further progress in the quarters to come.

    For the year ended December 31, 2011, cash flow from operating activities was $5.2 million, as compared to $7.8 million in 2010.  Most of this decline were due to lower net income and higher working capital usage from higher inventory levels and lower accounts payables in 2011 compared to 2010.

    "In 2012, we anticipate adding new higher-margin revenue streams from our upcoming new products, which should help buffer some of the margin pressures coming from competitive pricing due to government healthcare reform policies.
    Overall we are optimistic that we have the right mix of products and new product pipeline to position China Pharma to benefit from China's unprecedented healthcare reform program," said Ms. Li.  "We believe our success in 2012 and beyond will be defined by our differentiated products, promising pipeline, strong distribution network, and commercialization expertise."

    Pipeline UpdateAs of December 31, 2011, China Pharma had various pipeline drugs in different stages of active development.  Some of these are highlighted below:

  • The Company originally submitted application for production approval of Candesartan, a front-line drug therapy developed for the treatment of hypertension, in 2010. The Company received request for additional procedures in the fourth quarter of 2011 and has since completed all newly requested procedures. We now expect SFDA to give us the final production approval by mid-year 2012.
  • The Company completed clinical trials of Rosuvastatin, a generic form of Crestor, and is in the process of production approval.
  • The Company completed Phase I clinical trials of its novel cephalosporin-based combination antibiotic in September 2010.  We are currently conducting Phase II clinical trials for this drug.
  • The Company is developing a medicine for the treatment of coronary heart disease. This product comes with a patented TCM formula and we are currently conducting Phase III clinical trials for this drug. We anticipate the completion of the clinical work for this product by year end 2012.
  • Conference CallThe Company will hold a conference call at 8:30 am ET on March 15, 2012 to discuss fiscal year 2011 results.  Listeners may access the call by dialing 1-866-519-4004 or 65-672-393-81 for international callers, Conference ID # 59409919. A webcast will also be available through CPHI's website at  A replay of the call will be accessible through March 22, 2012 by dialing 1-866-214-5335 or 61-282-355-000 for international callers, Conference ID # 59409919.

    About China Pharma Holdings, Inc. China Pharma Holdings, Inc. is a rapidly growing specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high-margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit

    Safe Harbor Statement Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as the achievability of financial guidance, success of new product development, unanticipated changes in product demand, increased competition, downturns in the Chinese economy, uncompetitive levels of research and development, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations except as required by applicable law or regulation.

    China Pharma Holdings, Inc.
    Phone: +86-898-6681-1730 (China) 


     December 31, December 31, 

     2011 2010ASSETS 



     Current Assets: 



     Cash and cash equivalents




    3,692,086Banker's acceptances




    -Trade accounts receivable, less allowance for doubtful




     accounts of $3,536,405 and $3,317,017, respectively




    61,947,737Other receivables, less allowance for doubtful




     accounts of $38,921 and $15,669, respectively




    65,019Advances to suppliers








    20,388,935Deferred tax assets




    528,684Total Current Assets 



    91,934,357Advances for purchases of property and equipment 



    114,946Advances for purchases of intangible assets 



    29,781,388Property and equipment, net of accumulated depreciation of 



     $3,391,124 and $3,436,182, respectively




    6,372,487Intangible assets, net of accumulated amortization of 



     $3,041,804 and $2,342,081, respectively




    3,547,763TOTAL ASSETS 

    $  156,390,991


    $  131,750,941 







     Current Liabilities: 



     Trade accounts payable




    4,937,781Accrued expenses




    98,206Accrued taxes payable




    2,386,019Other payables




    92,077Advances from customers




    1,208,988Other payables - related parties




    303,644Short-term notes payable




    3,781,119Total Current Liabilities 



    12,807,834Long-term deferred tax liability 



    71,673Derivative warrant liability 



    934,260Total Liabilities 



    13,813,767Stockholders' Equity: 



     Preferred stock, $0.001 par value; 5,000,000 shares authorized;




     no shares issued or outstanding




    -Common stock, $0.001 par value; 95,000,000 shares authorized;




     43,529,557 shares and 43,404,557 shares outstanding, respectively




    43,405Additional paid-in capital




    23,252,476Retained earnings




    85,017,024Accumulated other comprehensive income




    9,624,269Total Stockholders' Equity 




    $  156,390,991


    $  131,750,941 









     For the Years Ended  

     December 31,  

     2011 2010 Revenue


    $ 81,166,739


    $ 74,388,180

     Cost of revenue










     Gross profit










     Operating expenses:





     Selling expenses





     General and administrative expenses





     Bad debt expense





     Total operating expenses










     Government subsidy income















     Income from operations










     Other income (expense):





     Interest income





     Interest expense





     Derivative gain





     Net other income










     Income before income taxes





     Income tax expense





     Net income 









     Other comprehensive income - foreign currency





     translation adjustment





     Comprehensive income 

    $ 24,349,740


    $ 27,135,809






     Earnings per Share: 




















     For the Years Ended 

     December 31, 

     2011 2010Cash Flows from Operating Activities: 



     Net income


    $ 19,269,642


    $ 23,414,347Depreciation and amortization




    1,505,195Stock based compensation




    345,416Derivative gain




    (1,588,888)Bad debt expense




    505,224Deferred income taxes




    (123,177)Changes in assets and liabilities:




     Trade accounts and other receivables




    (9,231,358)Advances to suppliers








    (5,530,989)Trade accounts payable




    895,001Accrued expenses and other liabilities




    74,063Accrued taxes payable




    785,383Other payables




    (30,183)Advances from customers




    132,572Net Cash Provided by Operating Activities 







     Cash Flows from Investing Activities: 



     Net investment in banker's acceptances




    -Advances for purchases of property and equipment 




     and intangible assets




    (10,454,529)Purchase of property and equipment




    (63,852)Net Cash Used in Investing Activities 







     Cash Flows from Financing Activity: 



     Proceeds from issuance of notes payable




    3,687,996Payments of notes payable




    (3,835,515)Borrowings from related party




    227,903Proceeds from exercise of warrants




    2,583,000Net Cash Provided by Financing Activity 







     Effect of Exchange Rate Changes on Cash 



    126,843Net Increase in Cash 



    57,333Cash and Cash Equivalents at Beginning of Year




    3,634,753Cash and Cash Equivalents at End of Year 

    $   4,050,854


    $   3,692,086 




     Supplemental Cash Flow Information: 



     Cash paid for interest




    8,258Cash paid for income taxes




    2,839,548Supplemental Noncash Investing and Financing Activities: 



       Accounts payable for purchases of property and equipment




    ,160  Accounts receivable collected with banker's acceptances




    -  Inventory purchased with banker's acceptances









    SOURCE China Pharma Holdings, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Respiratory Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017
    2. QIAGEN Expands Access to State-of-the-art HPV Screening in China Through Co-marketing Agreement With KingMed Diagnostics
    3. EntreMed Initiates Plans for China Office
    4. China Kanghui Holdings to Report Fourth Quarter and Full Year 2011 Financial Results
    5. Cumberland Pharmaceuticals Signs Exclusive Licensing Agreement for China
    6. Access Pharmaceuticals Receives Final Marketing Approval From SFDA of China for MuGard
    7. Boston Scientific Announces First Implants of TELIGEN® Implantable Defibrillator in China
    8. The Prostate Cancer Foundation Builds Momentum in China
    9. China Laboratory and Medical Sterilization Equipment and Apparatus Manufacturing Industry, 2012
    10. China Sky One Medical Reiterates CEO Sick Leave and Announces Significant Middle Management Resignations
    11. 3SBio Inc. to Present at the Oppenheimer & Co. 6th Annual China Dragon Conference
    Post Your Comments:
    (Date:11/24/2015)... Nov. 24, 2015   HeartWare International, Inc . ... miniaturized circulatory support technologies that are revolutionizing the treatment ... Chief Executive Officer Doug Godshall is scheduled ... Annual Healthcare Conference on December 1, 2015 at 3:00 ... in New York . ...
    (Date:11/24/2015)... BERN, Switzerland , November 24, 2015 /PRNewswire/ ... Biomedical Engineering Research of the University of ... Diabetes and Clinical Nutrition of the Bern University Hospital ... exclusive collaboration to develop a novel generation artificial pancreas. ... delivery of insulin for diabetic patients with the unequalled ...
    (Date:11/24/2015)... 2015 F1000Workspace - a research ... it was launched just six months ago. --> ... platform for scientists - since it was launched just six ... loaded on to F1000Workspace - a research collaboration, ... was launched just six months ago. --> ...
    Breaking Medicine Technology:
    (Date:11/24/2015)... ... November 24, 2015 , ... American Family Care (AFC), the nation’s ... a holiday pop-up clinic located in Metro Atlanta’s North Point Mall. The clinic is ... different way. The location is scheduled to operate through Dec. 24. , Holiday Pop-Up ...
    (Date:11/24/2015)... CT (PRWEB) , ... November 24, 2015 , ... Aided ... (WCHN) today announced an innovative study designed to yield insights into how to detect ... development of biomarkers for pancreatic cancer from small, non-coding RNA molecules (ncRNA), genetic material ...
    (Date:11/24/2015)... ... November 24, 2015 , ... ... Cleveland University-Kansas City (CU-KC), in Overland Park, Kansas. Benson, a fifth-trimester ... University President Carl S. Cleveland III on October 16. , “Katie is very ...
    (Date:11/24/2015)... ... November 24, 2015 , ... ... Healthy Aging Program have announced their endorsement of the Medical Fitness Network ... Fitness is proud to have the MFN as one of our endorsed organizations,” ...
    (Date:11/24/2015)... Warsaw, IN (PRWEB) , ... November 24, 2015 , ... ... in his office to help the community stress less this holiday season. During ... unnecessary additional stress in people's lives and the team at AlignLife want to help ...
    Breaking Medicine News(10 mins):